Physician profile
Sue E Meyer
NPI 1891785614
$417.82
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2021: $89.21 · 2022: $20.24.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103.98 | 2019-2021 | |
| Astellas Pharma US INC | $48.83 | 2019 | |
| Amgen INC. | $44.21 | 2019 | |
| Pfizer INC. | $40.74 | 2019-2021 | |
| Novo Nordisk INC | $26.77 | 2019 | |
| Merck Sharp & Dohme LLC | $23.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.60 | 2019 | |
| Glaxosmithkline, LLC. | $12.50 | 2019 | |
| Radius Health, INC. | $11.78 | 2019 | |
| Lilly USA, LLC | $11.71 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.